17,275 results match your criteria model parkinson's


Variability in subthalamic nucleus targeting for deep brain stimulation with 3 and 7 Tesla magnetic resonance imaging.

Neuroimage Clin 2021 Sep 16;32:102829. Epub 2021 Sep 16.

Integrative Model-based Cognitive Neuroscience Research Unit, University of Amsterdam, Amsterdam, The Netherlands.

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective surgical treatment for Parkinson's disease (PD). Side-effects may, however, be induced when the DBS lead is placed suboptimally. Currently, lower field magnetic resonance imaging (MRI) at 1. Read More

View Article and Full-Text PDF
September 2021

Angiotensin-(1-7) reduces α-synuclein aggregation by enhancing autophagic activity in Parkinson's disease.

Neural Regen Res 2022 May;17(5):1138-1145

Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China.

Abnormal accumulation of α-synuclein contributes to the formation of Lewy bodies in the substantia nigra, which is considered the typical pathological hallmark of Parkinson's disease. Recent research indicates that angiotensin-(1-7) plays a crucial role in several neurodegenerative disorders, including Parkinson's disease, but the underlying mechanisms remain elusive. In this study, we used intraperitoneal administration of rotenone to male Sprague-Dawley rats for 4 weeks to establish a Parkinson's disease model. Read More

View Article and Full-Text PDF

Predicting Motor Outcome of Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease Using Quantitative Susceptibility Mapping and Radiomics: A Pilot Study.

Front Neurosci 2021 7;15:731109. Epub 2021 Sep 7.

Department of Radiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Background: Emerging evidence indicates that iron distribution is heterogeneous within the substantia nigra (SN) and it may reflect patient-specific trait of Parkinson's Disease (PD). We assume it could account for variability in motor outcome of subthalamic nucleus deep brain stimulation (STN-DBS) in PD.

Objective: To investigate whether SN susceptibility features derived from radiomics with machine learning (RA-ML) can predict motor outcome of STN-DBS in PD. Read More

View Article and Full-Text PDF
September 2021

Characterizing the Retinal Phenotype of the Thy1-h[A30P]α-syn Mouse Model of Parkinson's Disease.

Front Neurosci 2021 7;15:726476. Epub 2021 Sep 7.

Research Group of Neural Circuit Development and Regeneration, Department of Biology, KU Leuven, Leuven, Belgium.

Despite decades of research, disease-modifying treatments of Parkinson's disease (PD), the second most common neurodegenerative disease worldwide, remain out of reach. One of the reasons for this treatment gap is the incomplete understanding of how misfolded alpha-synuclein (α-syn) contributes to PD pathology. The retina, as an integral part of the central nervous system, recapitulates the PD disease processes that are typically seen in the brain, and retinal manifestations have emerged as prodromal symptoms of the disease. Read More

View Article and Full-Text PDF
September 2021

Reduced dopamine signaling impacts pyramidal neuron excitability in mouse motor cortex.

eNeuro 2021 Sep 23. Epub 2021 Sep 23.

Dept. of Neurobiology and Behavior, SUNY - Stony Brook, Stony Brook, NY

Dopaminergic modulation is essential for the control of voluntary movement, however the role of dopamine in regulating the neural excitability of the primary motor cortex (M1) is not well understood. Here, we investigated two modes by which dopamine influences the input/output function of M1 neurons. To test the direct regulation of M1 neurons by dopamine, we performed whole-cell recordings of excitatory neurons and measured excitability before and after local, acute dopamine receptor blockade. Read More

View Article and Full-Text PDF
September 2021

Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice.

Neuropharmacology 2021 Sep 20:108784. Epub 2021 Sep 20.

Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, (Québec), G1V4G2, Canada; Faculté de Pharmacie, Pavillon Ferdinand-Vandry, 1050, avenue de la Médecine, Université Laval, Québec, (Québec) G1V 0A6, Canada. Electronic address:

The maisn neuropathological feature of Parkinson's disease (PD) is degeneration of dopamine neurons (DA) in the substantia nigra (SN); PD prevalence is higher in men, suggesting a role of sex hormones in neuroprotection. This study sought the effects of sex hormones in the brain in a mouse model of PD and modulation of steroid metabolism/synthesis with the 5α-reductase inhibitor dutasteride shown to protect MPTP male mice. Male and female mice were gonadectomized (GDX) or SHAM operated. Read More

View Article and Full-Text PDF
September 2021

Neuroprotective effect of bone marrow derived mesenchymal stem cell secretome in 6-OHDA-induced Parkinson's disease.

Regen Med 2021 Sep 23. Epub 2021 Sep 23.

Department of Pharmacology, Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, India.

The aim of the study was to evaluate the neuroprotective effect of bone marrow stem cell secretome in the 6-hydroxydopamine (6-OHDA) model of Parkinson's disease. Secretome prepared from mesenchymal stem cells of 3-month-old rats was injected daily for 7 days between days 7 and 14 after 6-OHDA administration. After 14 days, various neurobehavioral parameters were conducted. Read More

View Article and Full-Text PDF
September 2021

Identification of a Chlorogenic Ester as a Monoamine Oxidase (MAO-B) Inhibitor by Integrating "Traditional and Machine Learning" Virtual Screening and In Vitro as well as In Vivo Validation: A Lead against Neurodegenerative Disorders?

ACS Chem Neurosci 2021 Sep 23. Epub 2021 Sep 23.

Centre of Advanced Study in Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai 600025, Tamil Nadu, India.

Parkinson's disease (PD) is the furthermost motor disorder of adult-onset dementia connected to memory and other cognitive abilities. Monoamine oxidases (MAOs) have gained significant attention in recent years owing to their possible therapeutic use against PD. Expression of MAO-B has been found to be elevated in PD patients for increased uptake of dopamine, producing hydrogen peroxide and finally causing neuronal injury. Read More

View Article and Full-Text PDF
September 2021

Optimized pharmacological control over the AAV-Gene-Switch vector for regulable gene therapy.

Mol Ther Methods Clin Dev 2021 Dec 8;23:1-10. Epub 2021 Aug 8.

University Medical Center Göttingen, Department of Neurology, Waldweg 33, 37073 Göttingen, Germany.

Gene therapy in its current design is an irreversible process. It cannot be stopped in case of unwanted side effects, nor can expression levels of therapeutics be adjusted to individual patient's needs. Thus, the Gene-Switch (GS) system for pharmacologically regulable neurotrophic factor expression was established for treatment of parkinsonian patients. Read More

View Article and Full-Text PDF
December 2021

Interactions and Cytotoxicity of Human Neurodegeneration- Associated Proteins Tau and α-Synuclein in the Simple Model .

Front Cell Dev Biol 2021 6;9:741662. Epub 2021 Sep 6.

Department of Physiology, Anatomy and Microbiology, La Trobe University, Bundoora, VIC, Australia.

The abnormal accumulation of the tau protein into aggregates is a hallmark in neurodegenerative diseases collectively known as tauopathies. In normal conditions, tau binds off and on microtubules aiding in their assembly and stability dependent on the phosphorylation state of the protein. In disease-affected neurons, hyperphosphorylation leads to the accumulation of the tau protein into aggregates, mainly neurofibrillary tangles (NFT) which have been seen to colocalise with other protein aggregates in neurodegeneration. Read More

View Article and Full-Text PDF
September 2021

Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia.

Commun Biol 2021 Sep 22;4(1):1071. Epub 2021 Sep 22.

Department of Molecular, Cellular and Biomedical Sciences, CUNY School of Medicine at City College of New York, City University of New York, New York, NY, USA.

L-Dopa induced dyskinesia (LID) is a debilitating side effect of dopamine replacement therapy for Parkinson's Disease. The mechanistic underpinnings of LID remain obscure. Here we report that diminished sonic hedgehog (Shh) signaling in the basal ganglia caused by the degeneration of midbrain dopamine neurons facilitates the formation and expression of LID. Read More

View Article and Full-Text PDF
September 2021

Magnetothermal nanoparticle technology alleviates parkinsonian-like symptoms in mice.

Nat Commun 2021 Sep 22;12(1):5569. Epub 2021 Sep 22.

Department of Neurosurgery, Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.

Deep brain stimulation (DBS) has long been used to alleviate symptoms in patients suffering from psychiatric and neurological disorders through stereotactically implanted electrodes that deliver current to subcortical structures via wired pacemakers. The application of DBS to modulate neural circuits is, however, hampered by its mechanical invasiveness and the use of chronically implanted leads, which poses a risk for hardware failure, hemorrhage, and infection. Here, we demonstrate that a wireless magnetothermal approach to DBS (mDBS) can provide similar therapeutic benefits in two mouse models of Parkinson's disease, the bilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and in the unilateral 6-hydroxydopamine (6-OHDA) model. Read More

View Article and Full-Text PDF
September 2021

A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons.

Elife 2021 09 22;10. Epub 2021 Sep 22.

Department of Bioengineering and Therapeutic Sciences and Programs in BiologicalSciences and Human Genetics, University of California, San Francisco, San Francisco, United States.

Parkinson's disease (PD) is a common neurodegenerative disorder without effective disease-modifying therapeutics. Here, we establish a chemogenetic dopamine (DA) neuron ablation model in larval zebrafish with mitochondrial dysfunction and robustness suitable for high-content screening. We use this system to conduct an in vivo DA neuron imaging-based chemical screen and identify the Renin-Angiotensin-Aldosterone System (RAAS) inhibitors as significantly neuroprotective. Read More

View Article and Full-Text PDF
September 2021

A long-term community gym program for people with Parkinson's disease: a feasibility study of the Monash Health "Health and Fitness" model.

Disabil Rehabil 2021 Sep 21:1-9. Epub 2021 Sep 21.

Clinical Research Centre for Movement Disorders and Gait, Parkinson's Foundation Center of Excellence, Monash Health, Kingston Centre, Melbourne, Australia.

Purpose: To investigate the feasibility and acceptability of the Health and Fitness Program (HFP), a long-term community gym program for people with mild to moderate Parkinson's disease (PD).

Methods: Physiotherapists, with PD expertise, developed individualised exercise programs for new HFP members in consultation with them. Gym instructors, with PD training, supervised the HFP sessions. Read More

View Article and Full-Text PDF
September 2021

7,8-dihydroxyflavone ameliorates motor deficits via regulating autophagy in MPTP-induced mouse model of Parkinson's disease.

Cell Death Discov 2021 Sep 20;7(1):254. Epub 2021 Sep 20.

Pediatric Research Institute, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China.

Parkinson's disease (PD) is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra and diminished dopamine content in the striatum. Recent reports show that 7,8-dihydroxyflavone (DHF), a TrkB agonist, attenuates the α-synuclein deposition and ameliorates motor deficits. However, the underlying mechanism is unclear. Read More

View Article and Full-Text PDF
September 2021

Acute effects of acupuncture in balance and gait of Parkinson disease patients - A preliminary study.

Complement Ther Clin Pract 2021 Sep 8;45:101479. Epub 2021 Sep 8.

ICBAS-Abel Salazar Institute for Biomedical Sciences, University of Porto, Portugal; Escola Superior de Saúde, Piaget Institute, Vila Nova de Gaia, Portugal.

Introduction: Balance and gait disorders are relevant symptoms in the quality of life of Parkinson's patients. Currently, there is no therapy to reverse or treat this condition. Acupuncture treatment is believed to improve motor ability through the cortico-basal-thalamus-cortical-ganglia. Read More

View Article and Full-Text PDF
September 2021

The effects of a simulated fMRI environment on voice intensity in individuals with Parkinson's disease hypophonia and older healthy adults.

J Commun Disord 2021 Aug 31;94:106149. Epub 2021 Aug 31.

Roxelyn and Richard Pepper Department of Communication Sciences and Disorders, Northwestern University, Evanston, IL.

Purpose: Functional magnetic resonance imaging (fMRI) has promise for understanding neural mechanisms of neurogenic speech and voice disorders. However, performing vocal tasks within the fMRI environment may not always be analogous to performance outside of the scanner. Using a mock MRI scanner, this study examines the effects of a simulated scanning environment on vowel intensity in individuals with Parkinson's disease (PD) and hypophonia and older healthy control (OHC) participants. Read More

View Article and Full-Text PDF

LRRK2 and WAVE2 regulate microglial-transition through distinct morphological phenotypes to induce neurotoxicity in a novel two-hit in vitro model of neurodegeneration.

J Cell Physiol 2021 Sep 20. Epub 2021 Sep 20.

Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada.

We report a novel in vitro classification system that tracks microglial activation state and their potential neurotoxicity. Mixed live-cell imaging was used to characterize transition through distinct morphological phenotypes, production of reactive oxygen species (ROS), formation of reactive microglial aggregates, and subsequent cytokine production. Transwell cultures were used to determine microglial migration (control and lipopolysaccharide (LPS) treated) to glutamate pre-stressed or healthy neurons. Read More

View Article and Full-Text PDF
September 2021

Deficiency of leads to accelerated aging and neuroprotection in MPTP-induced Parkinson's disease mice.

Aging (Albany NY) 2021 Sep 20;13(undefined). Epub 2021 Sep 20.

Department of Translational Neuroscience, Jing'an District Centre Hospital of Shanghai, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China.

Studies reveal a linkage of miR-29s in aging and Parkinson's disease (PD). Here we show that the serum levels of miR-29s in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice exhibited dynamic changes. The role of in aging and PD was studied utilizing gene knockout mice ( KO). Read More

View Article and Full-Text PDF
September 2021

Restoration of Parkinson's Disease-Like Deficits by Activating Autophagy through mTOR-Dependent and mTOR-Independent Mechanisms in Pharmacological and Transgenic Models of Parkinson's Disease in Mice.

Bull Exp Biol Med 2021 Sep 20. Epub 2021 Sep 20.

Research Institute of Neurosciences and Medicine, Novosibirsk, Russia.

We studied the possibilities of inhibition of neurodegeneration in MPTP-induced model of Parkinson's disease (PD) in C57Bl/6J mice and transgenic model of early PD stage (5-monthold B6.Cg-Tg(Prnp-SNCA*A53T)23Mkle/J mice) by autophagy activation through mTOR-dependent and mTOR-independent pathways with rapamycin and trehalose, respectively. Therapy with autophagy inducers in a "postponed" mode (7 days after MPTP intoxication) restored the expression of the dopaminergic neuron marker tyrosine hydroxylase and markedly improved cognitive function in the conditioned passive avoidance response (CPAR; fear memory). Read More

View Article and Full-Text PDF
September 2021

The Effect of Reminiscence Therapy Using Virtual Reality on Apathy in Residential Aged Care: Multisite Nonrandomized Controlled Trial.

J Med Internet Res 2021 Sep 20;23(9):e29210. Epub 2021 Sep 20.

UniSA Justice & Society, University of South Australia, Adelaide, South Australia, Australia.

Background: Apathy is a frequent and underrecognized neurological disorder symptom. Reduced goal-directed behavior caused by apathy is associated with poor outcomes for older adults in residential aged care. Recommended nonpharmacological treatments include person-centered therapy using information and communication technology. Read More

View Article and Full-Text PDF
September 2021

Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinson's Disease.

J Parkinsons Dis 2021 Sep 16. Epub 2021 Sep 16.

Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea.

Background: Premorbid educational attainment is a well-known proxy of reserve, not only with regard to cognition, but also to motor symptoms.

Objective: In the present study, we investigated the relationship between educational attainment and long-term motor prognosis in patients with Parkinson's disease (PD).

Methods: We analyzed 466 patients with de novo PD without dementia who underwent dopamine transporter (DAT) scans and were followed up more than 2 years. Read More

View Article and Full-Text PDF
September 2021

Advanced brain ageing in Parkinson's disease is related to disease duration and individual impairment.

Brain Commun 2021 23;3(3):fcab191. Epub 2021 Aug 23.

Institute of Neuroscience and Medicine (INM-1, INM-7, INM-11), Jülich, Germany.

Machine learning can reliably predict individual age from MRI data, revealing that patients with neurodegenerative disorders show an elevated biological age. A surprising gap in the literature, however, pertains to Parkinson's disease. Here, we evaluate brain age in two cohorts of Parkinson's patients and investigated the relationship between individual brain age and clinical characteristics. Read More

View Article and Full-Text PDF

lncRNA PART1 mitigates MPP-induced neuronal injury in SH-SY5Y cells via micRNA-106b-5p/MCL1 axis.

Am J Transl Res 2021 15;13(8):8897-8908. Epub 2021 Aug 15.

Department of Orthopedics, The First Affiliated Hospital, Harbin Medical University Harbin, Heilongjiang Province, China.

Objective: Parkinson's disease (PD) is a neurodegenerative disease caused by the loss of dopaminergic neurons. Here, we aimed to explore the function of LncRNA PART1 in PD and its underlying mechanisms.

Methods: An MPTP-induced mouse model of PD was generated and the SH-SY5Y cells were treated with MPP to induce neuronal damage . Read More

View Article and Full-Text PDF

Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy.

Neurobiol Dis 2021 Sep 16:105509. Epub 2021 Sep 16.

Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health and the University of Melbourne, Parkville, Victoria, Australia.

Multiple System Atrophy (MSA) is a rare neurodegenerative synucleinopathy which leads to severe disability followed by death within 6-9 years of symptom onset. There is compelling evidence suggesting that biological trace metals like iron and copper play an important role in synucleinopathies like Parkinson's disease and removing excess brain iron using chelators could slow down the disease progression. In human MSA, there is evidence of increased iron in affected brain regions, but role of iron and therapeutic efficacy of iron-lowering drugs in pre-clinical models of MSA have not been studied. Read More

View Article and Full-Text PDF
September 2021

N-γ-(L-glutamyl)-L-selenomethionine shows neuroprotective effects against Parkinson's disease associated with SKN-1/Nrf2 and TRXR-1 in Caenorhabditis elegans.

Phytomedicine 2021 Sep 4;92:153733. Epub 2021 Sep 4.

Department of Bioenvironmental Systems Engineering, National Taiwan University, No. 1 Roosevelt Road, Sec. 4, Taipei 106, Taiwan. Electronic address:

Background: Parkinson's disease (PD) is a common neurodegenerative disease, yet fundamental treatments for the disease remain sparse. Thus, the search for potentially efficacious compounds from medicinal plants that can be used in the treatment of PD has gained significant interest.

Purpose: In many medicinal plants, selenium is primarily found in an organic form. Read More

View Article and Full-Text PDF
September 2021

Heterozygous GBA D490V and ATP13a2 mutations do not exacerbate pathological α-synuclein spread in the prodromal preformed fibrils model in young mice.

Neurobiol Dis 2021 Sep 16;159:105513. Epub 2021 Sep 16.

Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA. Electronic address:

Autophagic dysregulation and lysosomal impairment have been implicated in the pathogenesis of Parkinson's disease, partly due to the identification of mutations in multiple genes involved in these pathways such as GBA, SNCA, ATP13a2 (also known as PARK9), TMEM175 and LRRK2. Mutations resulting in lysosomal dysfunction are proposed to contribute to Parkinson's disease by increasing α-synuclein levels, that in turn may promote aggregation of this protein. Here, we used two different genetic models-one heterozygous for a mutated form of the GBA protein (D409V), and the other heterozygous for an ATP13a2 loss-of-function mutation, to test whether these mutations exacerbate the spread of α-synuclein pathology following injection of α-synuclein preformed fibrils in the olfactory bulb of 12-week-old mice. Read More

View Article and Full-Text PDF
September 2021

Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment.

Neurosci Lett 2021 Sep 15:136251. Epub 2021 Sep 15.

University of Arizona, College of Nursing, 1305 N. Martin Ave, P.O. Box 210203, Tucson, AZ 85721, USA. Electronic address:

Parkinson's disease (PD) is a neurodegenerative disease caused by the death of dopaminergic neurons in the substantia nigra pars compacta (SNpc), characterized by motor dysfunction. While PD symptoms are well treated with L-DOPA, continuous use can cause L-DOPA-induced dyskinesia (LID). We have previously demonstrated that sub-anesthetic ketamine attenuated LID development in rodents, measured by abnormal involuntary movements (AIMs), and reduced the density of maladaptive striatal dendritic mushroom spines. Read More

View Article and Full-Text PDF
September 2021

Silibinin ameliorates depression/anxiety-like behaviors of Parkinson's disease mouse model and is associated with attenuated STING-IRF3-IFN-β pathway activation and neuroinflammation.

Physiol Behav 2021 Sep 15;241:113593. Epub 2021 Sep 15.

Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China; Key Laboratory of Computational Chemistry-Based Natural Antitumor Drug Research & Development, Liaoning, China. Electronic address:

Depression and anxiety are common neuropsychiatric symptom of Parkinson's disease (PD), reflecting reduced quality of life in patients with PD. Silibinin (silybin), a flavonoid extracted and isolated from the fruit of Silybum marianum (L.) Gaertn, is widely used for the treatment of hepatic diseases. Read More

View Article and Full-Text PDF
September 2021

Blockade of adenosine A receptors inhibits Tremulous Jaw Movements as well as expression of zif-268 and GAD65 mRNAs in brain motor structures.

Behav Brain Res 2021 Sep 16;417:113585. Epub 2021 Sep 16.

Department of Neuropsychopharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, 12 Smętna Street, 31-343, Kraków, Poland. Electronic address:

Tremor is one of the motor symptoms of Parkinson's disease (PD), present also in neuroleptic-induced parkinsonism. Tremulous Jaw Movements (TJMs) are suggested to be a well-validated rodent model of PD resting tremor. TJMs can be induced by typical antipsychotics and are known to be reduced by different drugs, including adenosine A receptor antagonists. Read More

View Article and Full-Text PDF
September 2021